CABA 株価推移チャート
CABA 株価予測
Cabaletta Bio Inc
$3.73
-10.12%
$-0.42
終値： May 06, 16:00:00 GMT-4
$3.63
-2.68%
$-0.1
アフターマーケット：May 06, 20:00:00 GMT-4
戻る
Cabaletta Bio Inc (CABA) 株価予測
主要データ
前終値
$4.15
始値
$4.16
当日レンジ
$3.53 - $4.22
52週レンジ
$1.06 - $3.78
取引高
6.7M
平均取引高
2.6M
配当利回り
--
1株当たり利益(TTM)
-2.28
時価総額
$404.0M
CABAとは何ですか？
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
